放疗联合免疫治疗在局部晚期不可切除食管癌中的研究进展OACSTPCD
Research Progress of Radiotherapy Combined with Immunotherapy in the Treatment of Locally Advanced Unresectable Esophageal Cancer
随着食管癌进入免疫治疗时代,食管癌的治疗模式发生了彻底的改变.目前免疫治疗已被推荐作为晚期食管癌的一线治疗.然而,对于局部晚期不可切除食管癌,目前的标准治疗仍然是根治性放化疗,患者预后较差.已有研究表明放疗与免疫治疗联合可产生协同作用.本文就放疗联合免疫治疗的作用机制,及其在局部晚期不可切除食管癌中的临床研究进行综述.
With the emergence of immunotherapy,the treatment of esophageal cancer has been undergoing a profound transformation.Currently,immunotherapy is recommended as the first-line therapy for advanced esophageal cancer.However,for patients with locally advanced and unresectable esophageal cancer,the current standard treatment remains radical radio-therapy combined with chemotherapy,often resulting in unfavorable prognosis.Nevertheless,accumulating evidence suggests that the combination of radiotherapy and immunotherapy can yield synergistic effects.This article aims to comprehensively re-view the underlying mechanisms of this combined approach and its clinical applications in the management of locally ad-vanced and unresectable esophageal cancer.
谢良云;张志
050017 石家庄,河北医科大学研究生学院||063003 河北唐山,河北医科大学附属唐山市工人医院肿瘤内科063003 河北唐山,河北医科大学附属唐山市工人医院肿瘤内科
临床医学
食管癌放疗免疫治疗局部晚期不可切除研究进展
Esophageal cancerRadiotherapyImmunotherapyLocally advancedUnresectableResearch progress
《肿瘤预防与治疗》 2024 (12)
1076-1083,8
This study was supported by Natural Science Foundation of Hebei Province(No.H2023105018). 河北省自然科学基金(编号:H2023105018)
评论